<DOC>
	<DOCNO>NCT02691182</DOCNO>
	<brief_summary>Children age 6-12 year diagnose impulsive aggression comorbid ADHD participate 810P301 810P302 study invite participate study . This Phase 3 open label extension ( OLE ) study objective collect long-term safety data use SPN-810 treating impulsive aggression pediatric subject ADHD , take conjunction standard ADHD treatment . After confirmation eligibility , subject treat SPN-810.Subjects give choice extend participation study every 6 month 36 month .</brief_summary>
	<brief_title>Treatment Impulsive Aggression Subjects With ADHD Conjunction With Standard ADHD Treatment ( CHIME 4 )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<criteria>1 . Healthy male female subject , complete converted satisfactory participation study 810P301or 810P302 discontinue early previous study maintenance phase allow enroll consultation Investigator , Medical Monitor Sponsor . 2 . Medically healthy clinically normal laboratory profile , vital sign , electrocardiogram ( ECGs ) . 3 . Existing diagnosis ADHD , describe DSM5 confirm KSADS PL 2013 study 810P301 810P302 . 4 . Currently receive monotherapy treatment FDAapproved ADHD medication ( stimulant nonstimulants ) . 5 . Weight least 20 kg . 6 . Written Informed Consent obtain subject 's parent LAR , write Informed Assent obtain subject appropriate . 1 . Body Mass Index ( BMI ) 99th percentile . 2 . Clinically significant change health status , safety concern reason , opinion Sponsor Investigator , would prevent subject participate study successfully complete study . 3 . Pregnancy refusal practice contraception study ( female subject childbearing potential sexually active male ) . 4 . Current substance alcohol use . 5 . Suicidal thoughts behavior confirm last visit previous doubleblind randomize study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>